Expert Interview
A look at potential of acoramidis following the failure on Part A of the ATTRibute-CM study
Ticker(s): BBIO, PFE- Director of Cardiac Amyloidosis & Cardiac Transplantation program and Associate Professor, Medicine-Cardiology at the University of Colorado.
- Currently manages ~60 active ATTR cardiac amyloid patients and has prescribed Tafamidis.
- Research focuses on Cardiac Amyloidosis, Advanced Heart Failure, Cardiac Transplantation, and Mechanical Circulatory Support / Ventricular Assist Devices; has participated in multiple clinical trials investigating new pharmacologic and device therapies for patients with advanced heart failure and cardiac amyloidosis.
Roughly how many patients with amyloidosis do you currently manage?
Added By: user1ae2bf5fWhat are your thoughts on the anti-wt and mt amyloid ATTR antibody approach for this indication? Is there space in the treatment paradigm for these types of approach?
Added By: user5d2d4f30Alnylam's Onpattro is also being studied for use in this population. How do you that agent being used in your practice for the cm population?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
